MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Business/Financial News / Funding Roundup / Gynesonics tops off $46m round

Gynesonics tops off $46m round

November 18, 2015 By Brad Perriello Leave a Comment

GynesonicsGynesonics said the $2.9 million it just added to its coffers closed out a funding round totaling $46 million.

The round was led by USP Group’s Novit Ventures and included Endeavour Vision, Abingworth, HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.

Redwood City, Calif.-based Gynesonics makes the Sonata radiofrequency ablation device for treating uterine fibroids.

Gynesonics said the proceeds are earmarked for strategic initiatives and its clinical program, including a pivotal trial aimed at FDA approval for the latest Sonata iteration. The device is designed to use sonograph-guided radiofrequency ablation to destroy intrauterine fibroids while preserving the uterus.

“Our financial partners have great confidence in the potential of the Sonata technology platform to make a significant improvement in the lives of millions of women around the world who suffer from symptomatic uterine fibroids,” president & CEO Christopher Owens said in prepared remarks. “This total financing significantly increases the depth of our financial backing, enabling us to move forward aggressively in executing our clinical research initiatives, R&D priorities and initial European targeted commercialization.”

Last October, Gynesonics won an investigational device exemption from the FDA to start the Sonata pivotal trial to evaluate the safety and effectiveness of radiofrequency ablation as a treatment for heavy menstrual bleeding relating to symptomatic uterine fibroids. The trial is expected to expand to as many as 22 sites and enroll up to 147 patients.

Filed Under: Funding Roundup, Women's Health Tagged With: Gynesonics

In case you missed it

  • Vicarious Surgical wins FDA breakthrough designation for surgical robot
  • Natus Medical issues field safety notice for snap electrode leads
  • J&J’s Ethicon gets to substitute 20 new claims on surgical stapler patent
  • Minerva Surgical raises $10m
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • Study reveals long-term outcomes of Boston Scientific Watchman patients
  • 3M issues safety notice for Durapore Advanced surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise
  • TransMedics touts first U.S. ‘reanimated’ heart transplants
  • Micro-Leads collects $10m for neuromod therapy
  • Viant to cease ethylene oxide sterilization at Michigan plant by year’s end
  • Venclose closes $27m Series C
  • CSA Medical wins CE Mark approval for RejuvenAir System

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS